跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 98,190 条关于
“HR+ breast cancer”
全部
98,190
临床试验
79,335
药物
2,362
机构
1,171
资讯
15,322
去年
Dual mTORC1/2 Inhibitor BI 860585 Shows Promise in Phase I Breast Cancer Trial
去年
Relay Therapeutics' RLY-2608: A Mutant-Selective PI3Kα Inhibitor Enters Phase I Trials for HR+/HER2- Breast Cancer
去年
Triple-Drug Therapy Doubles Survival Time in Advanced Breast Cancer with PIK3CA Mutation
去年
Inavolisib Combination Therapy Doubles Progression-Free Survival in Advanced Breast Cancer
9个月前
Breast Cancer Index Test Shows Promise for Identifying Low-Risk Premenopausal Patients Who May Avoid Aggressive Therapy
去年
Puma Biotechnology Initiates Phase II Trial of Alisertib in HR+/HER2- Breast Cancer
4年前
Samuraciclib Plus Fulvestrant Shows Promising Results in Heavily Pretreated HR+ Breast Cancer
去年
Dalpiciclib Plus Letrozole Shows Promise in Phase II Trial for HR+/HER2- Breast Cancer
去年
Sanofi Halts Amcenestrant Development After Disappointing First-Line Breast Cancer Trial
6个月前
Novartis Acquires Next-Generation PI3Kα Inhibitor SNV4818 in $3 Billion Deal to Strengthen Breast Cancer Pipeline
第 1 页,共 1533 页
上一页
下一页